Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.
about
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideVasculogenesis: a crucial player in the resistance of solid tumours to radiotherapyReceptor tyrosine kinase-mediated angiogenesisMouse models for studying angiogenesis and lymphangiogenesis in cancerRiboTag analysis of actively translated mRNAs in Sertoli and Leydig cells in vivo.Vascular permeability--the essentialsZebrafish Caudal Fin Angiogenesis Assay-Advanced Quantitative Assessment Including 3-Way Correlative MicroscopyOptimized design and analysis of preclinical intervention studies in vivoSystematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsinEngineering cancer microenvironments for in vitro 3-D tumor models.The future of patient-derived tumor xenografts in cancer treatment.Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer.Stromal reengineering to treat pancreas cancerHuman cancer xenografts in outbred nude mice can be confounded by polymorphisms in a modifier of tumorigenesisEndothelial cell metabolism: parallels and divergences with cancer cell metabolismNeoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.Emerging roles of post-translational modifications in signal transduction and angiogenesisInoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine ModelTargeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas.Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer.Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy.First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorinationCompartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase.Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma.Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy.Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapyAnti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.The importance of comparative oncology in translational medicine.Adapting Cancer Immunotherapy Models for the Real World.Non-alcoholic fatty liver disease-a chronic disease of the 21(st) century.Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancerMouse models of metastasis: progress and prospects.Endothelial adenosine A2a receptor-mediated glycolysis is essential for pathological retinal angiogenesis.Incomplete and transitory decrease of glycolysis: a new paradigm for anti-angiogenic therapy?RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.Tumor angiogenesis: putting a value on plastic GEMMs.
P2860
Q26770678-961A86EF-7F30-48B8-8944-11032AA5D019Q26999217-F99CE002-2A61-4FC5-BA4C-7A8227976CD8Q27001612-48E1A32A-D50E-4C6C-A16F-A57DAD839617Q27003898-D174A05B-BE42-488D-99F6-FF9AA27D9B9EQ27315140-0626772D-3DE5-423A-8D14-3CA78E13123CQ28085112-9B6E3B13-0959-45B4-AA2E-652C52AF8F7AQ28550573-EDAFBD8A-4872-4F70-B67C-B2934511EAEBQ28595545-EF924A10-2B7E-4B3C-B175-9A6DF6A67CDCQ28817780-F855EFB0-0888-4905-AB28-8DC497871F84Q30358020-C5C23272-19F0-476F-814B-7930B7E846F2Q33361578-3510292A-87DD-42F1-AC7F-E8C33B1F4740Q33443519-425BFED3-767C-4931-B671-3F99409F6B40Q33605281-A55EBCFB-3B37-4D16-B3D1-6204AC5928D7Q33827708-769CF7BA-0686-426F-9E28-010F20F5677DQ34016630-6DAADEAE-AA5C-4428-9833-5A509EB0333EQ34228247-251D7DCF-8FDD-4315-B36B-244CB67D4666Q34880943-BAB53503-34AF-41C4-A6B8-03DD48B67DAEQ34978408-56AD9662-D604-4B5A-B3FF-0339CC6EF42CQ36184480-84E0CF7A-2E65-45A0-8564-E07B3CB44CE1Q36332042-9B991E75-67E2-434F-B3F0-0721A65B7225Q36342854-39BCC8A8-A623-4C03-A933-40ABD1CD8E89Q36762385-95C269D3-263F-4806-AC02-5F17E39A9122Q36910309-7106ABBC-779A-4D88-89DD-3AFDC8452D15Q36931413-3B45184C-CCFA-45CB-BAC2-9153B4468AB6Q37054876-41DD50EC-F8AB-46CF-8EC6-81F432256A4EQ37081606-70626A5F-9674-4C35-B5C3-17AB9A16F757Q37119287-A492AC70-C079-4816-82EC-9DBEB4971BBCQ37335564-861CF530-CF50-4BC5-857B-243659FEE35DQ37524215-5794B77C-E937-4595-B79E-1CAC77F6EA5FQ38257830-C68C37BF-41F6-47C4-BEFA-A3B4000FEA68Q38263008-2A8411A1-2579-4FC7-B0A4-5080287D678FQ38303454-624E9FE9-EC22-4BB3-8BC5-DEC9381670F2Q38815212-ECEB055A-2316-4DA9-A697-BA96F74EB420Q39333577-D9EB69CD-86CE-4488-9A98-4FC4992DF7D5Q41561800-A1DAAB23-88B5-4344-98F7-5B5F0BD5F152Q41664785-442BA8E0-6057-4F8A-82B4-EC111419AECBQ41701186-59C5980E-1896-4382-BBC2-A957D68995ADQ41958219-6D0842B1-EC66-4374-A5AB-FFA13D90D75BQ41960947-41D0D66F-C8D0-4011-8D71-37A1D77164E9Q42728162-17D3839B-0414-4EBB-804F-5774F9EBC23B
P2860
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.
@en
type
label
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.
@en
prefLabel
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.
@en
P2860
P356
P1433
P1476
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.
@en
P2093
Mallika Singh
Napoleone Ferrara
P2860
P2888
P304
P356
10.1038/NBT.2286
P577
2012-07-10T00:00:00Z
P5875
P6179
1019615434